TuHURA Biosciences, Inc. Completes Strategic Acquisition of Kineta, Inc.

Key Highlights of the Transaction

• TuHURA Biosciences, Inc. (“TuHURA”) has completed the acquisition of Kineta, Inc. (“Kineta”) on June 30, 2025, through a two-step merger process. TuHURA is the accounting acquirer, and Kineta has become a wholly-owned subsidiary.
• Merger Consideration: The acquisition was paid for through a combination of cash and newly issued TuHURA common stock, with Kineta shareholders receiving approximately 7.6% of the combined company’s stock (estimated at 3,998,054 shares), and the remaining 92.4% owned by existing TuHURA shareholders.
• No Immediate Cash to Kineta Shareholders: The cash portion of the merger consideration for Kineta shareholders was effectively zero at closing, due to netting of prior advances and Kineta’s working capital deficit. Kineta shareholders’ primary compensation was newly issued TuHURA stock.
• Private Placement Raises \$12.6 Million: As a condition of the merger, TuHURA raised \$12.6 million in a private placement by selling 4,759,309 shares (with accompanying warrants) at \$2.65 per share, a 15% discount to the market price, strengthening the company’s cash position.
• Strategic Asset Acquisition: TuHURA acquired rights to Kineta’s novel antibody KVA12123 (now TBS-2025), expanding its pipeline and R&D capabilities.
• Business Combination Accounting: The deal is accounted for as a business combination under US GAAP, with TuHURA as the accounting acquirer. Goodwill of \$10.7 million and \$11.3 million in in-process R&D were recognized.
• Pro Forma Financials: The combined company reported a net loss of \$34.6 million for 2025, or a pro forma net loss per share of \$0.64, on 54.3 million weighted average shares outstanding.
• Potential Price Sensitive Information: Share issuance at a discount and expanded float, completed merger, pipeline expansion, and integration of Kineta’s assets could all materially affect TuHURA’s share value.

Detailed Transaction Summary

Merger Mechanics and Share Issuance

On December 11, 2024, TuHURA and Kineta signed a definitive merger agreement. The transaction closed on June 30, 2025, with TuHURA acquiring all Kineta shares through two sequential mergers. Kineta shareholders received 0.185298 shares of TuHURA common stock for each Kineta share, totaling 2,868,169 shares at closing, plus a further 1,129,885 shares to be issued six months post-close (subject to adjustment for any losses during this period).

No fractional shares were issued; cash in lieu was paid at \$5.7528 per share. As a result, all 15,478,657 Kineta shares were cancelled and converted into the right to receive the merger consideration.

June 2025 Private Placement

To fund operations and meet merger conditions, TuHURA completed a \$12.6 million private placement, issuing 4,759,309 shares and an equal number of warrants (exercise price: \$3.3125, expiring December 2030) at a unit price of \$2.65—a significant 15% discount to market price. The placement was conducted in four tranches, tied to regulatory and business milestones (FDA communication, trial initiation, merger closing).

All proceeds and share/warrant issuances are already reflected in TuHURA’s balance sheet as of September 30, 2025. The warrants are equity-classified and do not affect subsequent profit and loss.

Financial Impact of the Mergers

• Purchase Price and Allocation: Total estimated merger purchase price is \$16.56 million, comprised of \$7.64 million in cash (previously advanced), \$6.4 million in initial share consideration, and \$2.5 million in delayed shares. No contingent consideration (future asset sales) was recognized at closing.
• Net Assets Acquired: Kineta contributed \$390,721 in cash, \$11.3 million in in-process R&D, and \$10.7 million in goodwill, offset by \$5.8 million in assumed liabilities (accounts payable, notes, deferred tax).
• Pro Forma 2025 Results:
  • Operating loss: \$37.5 million
  • Total other income: \$1.62 million
  • Net loss attributable to common shareholders: \$34.6 million (\$0.64 per share)
  • Weighted average shares outstanding: 54.3 million
• Shareholder Dilution: The merger and private placement increase the number of outstanding TuHURA shares, resulting in dilution for existing shareholders but also providing significant new capital and pipeline assets.

What Shareholders Need to Know (Price Sensitive Events)

• Significant Share Issuance and Dilution: The merger and related financing increased the share count by over 10 million, with dilution offset by new capital and assets.
• Pipeline Expansion: Acquisition of Kineta’s lead asset (now TBS-2025) could drive future value, depending on clinical progress.
• Cash Position Strengthened: The private placement improves liquidity, supporting ongoing and future clinical trials.
• Regulatory Events: Certain tranches of the private placement are contingent on FDA decisions and clinical milestones, which can create future price-moving events.
• No Immediate Cash Out to Kineta Investors: All cash consideration was effectively netted against advances and working capital; Kineta investors mainly receive TuHURA stock.
• Potential for Additional Share Issuances: Delayed shares (subject to adjustments) and contingent payments tied to future asset sales may further increase the float.
• Goodwill and Intangibles: High recognition of goodwill and in-process R&D may signal the strategic value management foresees, but also could be subject to future impairment if expected synergies are not realized.
• Potential for Future Volatility: Integration risks, clinical development outcomes, and regulatory events tied to the acquired pipeline could all materially move the share price.

Conclusion

The merger of TuHURA and Kineta is a transformative deal, adding a novel clinical asset to TuHURA’s pipeline while strengthening its cash position through a discounted private placement. While the transaction brings dilution, it also sets the stage for potential pipeline-driven growth. Investors should pay close attention to further regulatory milestones, the issuance of delayed shares, and ongoing integration of Kineta’s programs, as each could materially impact TuHURA’s share price in the coming quarters.

Disclaimer

This news article is for informational purposes only and should not be construed as investment advice. The information is based on unaudited pro forma financial statements and is subject to change. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. Past performance is not indicative of future results. The company’s future performance may differ materially from the pro forma information presented above.

View TuHURA Biosciences, Inc./NV Historical chart here